<DOC>
	<DOCNO>NCT00407433</DOCNO>
	<brief_summary>These Phase 2 single-arm study gemcitabine combination oxaliplatin refractory relapse pediatric solid tumor .</brief_summary>
	<brief_title>Clinical Studies Gemcitabine-Oxaliplatin</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically cytologically confirm malignant solid tumor ( diagnosis ) Relapsed refractory tumor correct standard treatment approach fail Measurable primary and/or metastatic disease : least one bidimensionally measurable lesion . For patient neuroblastoma , measurable disease define modified International Neuroblastoma Staging System ( Brodeur et al.1993 ) . For patient osteosarcoma , measurable lesion lung metastasis osseous lesion soft tissue tumor , exclusion completely calcify necrosed lesion study entry . A patient unique osseous lesion without soft tissue mass include study lesion operable thus accessible histological response assessment . No one salvage therapy relapse Age inclusion : 6 month ≤ 20 year Lansky play score ≥ 70 % ECOG performance status ≤ 1 Life expectancy ≥ 3 month Adequate organ function : Adequate hematological function : neutrophil count &gt; = 1.0 x 10^9/L , platelet count &gt; = 100 x 10^9/L ; case bone marrow disease : &gt; = 75 x 10^9/L ; hemoglobin &gt; = 8 g/dL Adequate renal function : creatinine &gt; 1.5 x ULN age ; If serum creatinine &gt; 1.5 ULN age , creatinine clearance ( radioisotope GFR ) must &gt; 70 ml/min/1.73 m2 Adequate hepatic function : bilirubin &gt; 1.5 x ULN ; AST ALT &gt; 2.5 x ULN ( AST , ALT ≤ 5 x ULN case liver metastasis ) . Wash 3 week case prior chemotherapy , 6 week treatment include nitrosoureas , 2 week case vincristine alone ; 4 week case prior radiotherapy . Patients must recover acute toxic effect prior therapy enrollment study . Able comply schedule followup management toxicity All patient reproductive potential must practice effective method birth control study . Female patient childbearing potential must negative pregnancy test within 7 day study treatment . Written informed consent patient , parent legal guardian Concurrent administration antitumor therapy . Have previously complete withdrawn study study investigate gemcitabine oxaliplatin . Have serious concomitant systemic disorder ( example , active infection include HIV cardiac disease ) opinion investigator , would compromise patient 's ability complete study Preexisting sensory motor neuropathy &gt; Grade 2 ( exclude neuropathy due disease and/or surgery ) History allergic reaction platinum compound Are pregnant breast feed Presence symptomatic brain metastasis patient solid noncentral nervous system ( CNS ) tumor</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>Oxaliplatine</keyword>
	<keyword>Paediatric solid tumor</keyword>
	<keyword>Other CNS tumor</keyword>
	<keyword>Other miscellaneous solid non-CNS tumour</keyword>
</DOC>